ArticleAdvances in therapy2025

Pharmacokinetics and Safety of Ripretinib in Participants with Hepatic Impairment: A Phase 1 Study.

Anna Papinska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.